Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi AventisfiledCriticalSanofi Aventis
Publication of DOP2012000073ApublicationCriticalpatent/DOP2012000073A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems
(AREA)
Abstract
La invención se refiere a nuevos derivados de tomaimicina que comprenden un ligante. También se refiere a las moléculas de conjugado que comprenden uno o más de dichos derivados de tomaimicina unidos mediante enlaces covalentes a un agente de unión a la célula por un grupo de enlace que está presente en el ligante del derivado de tomaimicina. También se refiere a la preparación de los derivados de tomaimicina y de las moléculas de conjugado.The invention relates to novel tomaimycin derivatives comprising a binder. It also refers to the conjugate molecules comprising one or more of said tomaimycin derivatives linked by covalent bonds to a cell binding agent by a binding group that is present in the binder of the tomaimycin derivative. It also refers to the preparation of tomaimycin derivatives and conjugate molecules.
DO2012000073A2007-07-162012-03-19
CYTOTOXIC AGENTS UNDERSTANDING NEW TOMAIMYCIN DERIVATIVES AND THERAPEUTIC USE
DOP2012000073A
(en)
Leptomycin derived compound; conjugate comprising cell binding agent bound to one or more of said derivatives; pharmaceutical compositions comprising said derivative or conjugate; useful in the treatment of cancer; process of preparing a compound or a conjugate of a leptomycin derivative.
Substituted n-phenyl- (pyridin-3-yl) acetamide derivative compounds; pharmaceutical composition; preparation procedure; and its use to prevent or treat cancer.